RxDoctor Payments Data

Riaz Sirajuddin, MD

Cardiology · Oklahoma City, OKNPI 1235186099

Payments from drug & device makers

$291,065in general payments, 2019–2025

Across 1,156 payments — averaging $251.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$209K
  • Esperion Therapeutics, Inc.$33K
  • Johnson & Johnson$23K
  • Novartis$8K
  • Medtronic$4K
  • AstraZeneca$3K
  • plus $12K from 34 others

What the payments were for

  • Speaking & faculty fees$240,54683%
  • Travel & lodging$26,5859%
  • Food & beverage$23,6378%
  • Education$2970%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few cardiology providers in Oklahomato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$196,794
Medicare patients
342
Services billed
1,885

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban166$133,213
XareltoRivaroxaban153$106,994
OzempicSemaglutide91$93,852
Repatha SureclickEvolocumab94$82,982
EntrestoSacubitril/Valsartan70$82,236
TrulicityDulaglutide60$69,242
FarxigaDapagliflozin Propanediol77$53,786
MounjaroTirzepatide34$43,386
JardianceEmpagliflozin37$36,664
BrilintaTicagrelor68$33,455
KerendiaFinerenone26$28,314
TradjentaLinagliptin29$22,225
Praluent PenAlirocumab38$20,187
VascepaIcosapent Ethyl40$19,453
SynjardyEmpagliflozin/Metformin Hcl24$18,552

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,275$133,213166 claims
Lilly USA, LLCTrulicity, Mounjaro$334$112,62994 claims
Johnson & JohnsonXarelto$22,593$106,994153 claims
Novo NordiskOzempic$209,416$93,85291 claims
AstraZenecaFarxiga, Brilinta, Symbicort$2,737$90,259159 claims
Boehringer IngelheimJardiance, Tradjenta, Synjardy, Glyxambi$726$84,337102 claims
NovartisEntresto$7,901$82,23670 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$33,010$31,19353 claims
BayerKerendia$780$28,31426 claims
Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi$315$15,16142 claims
Kowa Pharmaceuticals America, Inc.Livalo, Bystolic$996$11,83531 claims
MerckJanuvia$508$7,46713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cardiology providers in Oklahomaon file to place this against a meaningful peer group, so we don't.

Other cardiology in Oklahoma City

Where these figures come from

Is this you, or does something look wrong? →